CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

GlobeNewswire Pharma
Original article

Curanex Highlights Five Additional Patient Cases Further Supporting the Potential of Its Lead Candidate in Cancer Cachexia, Advanced Cancer Supportive Care and Severe Systemic Decline

Data ReadoutpositivePositive
AI Analysis

Summary

Curanex presented five additional patient cases supporting its lead candidate for cancer cachexia and advanced cancer supportive care, including cases from thymic carcinoma, small cell lung cancer, pancreatic cancer, liver cirrhosis, and renal disease. The expanded case series provides observational evidence for the drug's potential across multiple disease indications.

Clinical Trial Data

Patients

5

Outcome Details

Expanded case series with five additional patient cases across advanced thymic carcinoma, small cell lung cancer, pancreatic cancer, end-stage liver cirrhosis, and end-stage renal disease

Importance:4/10
Sentiment:
0.60
cancer cachexiasupportive carecase serieslead candidateoncology
Related Companies

Read the original article

Published by GlobeNewswire Pharma on April 8, 2026 11:47 AM

Read Original